Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study

Peanut allergy is a potentially life-threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)-4/IL-13, improved safety and desensitization to peanut exposure in children with peanut all...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Allergy (Copenhagen) 2024-12
Hauptverfasser:	Sindher, Sayantani B, Nadeau, Kari C, Chinthrajah, R Sharon, Leflein, Jeffrey G, Bégin, Philippe, Ohayon, Jason A, Ponda, Punita, Wambre, Erik, Liu, Jinzhong, Khokhar, Faisal A, Akinlade, Bolanle, Maloney, Jennifer, Orengo, Jamie M, Hamilton, Jennifer D, Kamal, Mohamed A, Hooper, Andrea T, Patel, Naimish, Patel, Kiran, Laws, Elizabeth, Mannent, Leda P, Radin, Allen R
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Peanut allergy is a potentially life-threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)-4/IL-13, improved safety and desensitization to peanut exposure in children with peanut allergy. A Phase II, 24-week, multicenter, single-arm, open-label, proof-of-concept study was conducted in the USA and Canada (NCT03793608). Children/adolescents with peanut allergy received subcutaneous dupilumab 300 mg (≥ 60 kg) or 200 mg (≥ 20 to
ISSN:	1398-9995 1398-9995
DOI:	10.1111/all.16404